跳至主要内容
临床试验/NCT00000741
NCT00000741撤回3 期

A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients

National Institute of Allergy and Infectious Diseases (NIAID)6 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
撤回
试验地点
6

研究概览

简要总结

To determine the effect of methylprednisolone on respiratory failure in HIV-infected patients with presumed or confirmed pneumocystis carinii pneumonia who are stratified for presence or absence of respiratory failure at the time of randomization to the study.

详细描述

HIV-infected children are randomized to receive adjunctive therapy with intravenous methylprednisolone or placebo. Treatment is administered for 10 days. Primary antipneumocystis therapy with TMP/SMX or systemic pentamidine is selected by the individual investigator and given for 21 days. Patients are stratified at the time of randomization by the presence or absence of respiratory failure.

研究设计

研究类型
Interventional
干预模型
Parallel
主要目的
Treatment

入排标准

年龄范围
28 Days 至 2 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •Recombinant erythropoietin and any FDA-approved cytokine for management of anemia.
  • •Antiretroviral agents.
  • •Patients must have:
  • •Documented HIV infection.
  • •No more than 36 hours of prior primary therapy for confirmed or presumed PCP.
  • •Prior Medication:
  • •Up to 35 hours of primary therapy for confirmed or presumed PCP.

排除标准

  • •Co-existing Condition:
  • •Patients with the following symptoms and conditions are excluded:
  • •Demonstrated intolerance to steroids.
  • •Requirement for steroids at greater than physiological doses for other medical conditions.

研究者

研究点 (6)

Loading locations...

相似试验